NEATO-ROBOTICS
4.9.2020 13:32:20 CEST | Business Wire | Pressemeddelelse
Neato Robotics, en førende leverandør af intelligente robotstøvsugere til hjemmet, har i dag annonceret lanceringen af de nye modeller i deres kvalitetsserie – Neato D10, D9 og D8 – på IFA Berlin 2020. Neato-robotstøvsugere er den ultimative partner inden for rengøring, idet de har den bedste teknologi i klassen, nem indstilling og hardware, der er skabt til at holde.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200904005047/da/
"Vi har kombineret Neatos 15 års erfaring i branchen med kundefeedback og de seneste nyskabelser inden for robotteknologi og kunstig intelligens, og vi er glade for at kunne introducere disse fantastiske nye produkter – vores bedste indtil nu – for hele verden. Neatos nye serie af intelligente robotstøvsugere er unik i design og teknologi, med en førsteklasses brugeroplevelse og en ny MyNeato-app, som viser vores forpligtelse til at gøre hverdagen nemmere med robotteknologi", siger Neatos CEO, Thomas Nedder.
De nye Neato-robotstøvsugere har kvalitet og brugeroplevelse, der er bedst i deres klasse, samtidig med, at deres D-formede design, som er det første af sin art i branchen, har fået et løft. Neato-ejere kan nå fra hjørne til hjørne og fra kant til kant og få en mere komplet rengøring ved at bruge den bredeste børste og den største støvbeholder på markedet. Neato har det første originale HEPA-filter, og Neato D10 opfanger op til 99,97 % allergener og partikler såsom støv og skæl helt ned til 0,3 my. Det har aldrig været nemmere at indstille en Neato, med en Bluetooth-aktiveret tilslutning til wi-fi og effektiviseret sekstrins-proces på vores nye MyNeato-app – den korteste indstillingsproces i branchen – for straks at komme i gang med rengøringen.
Neato D10
Med en køretid på op til 150 minutter, et originalt HEPA-filter til at opfange op til 99,97 % allergener så små som 0,3 my samt den seneste LaserSmartTM LIDAR-baserede teknologi, er Neato D10 ultraydeevnen til den ultimative rengøring.
Neato D9
Neato D9 gør det beskidte arbejde for dig. Med et ultraydende filter i HEPA-stil, der opfanger 99,5 % støv og allergener, en køretid på op til 120 minutter samt Neatos signatur-teknologi, LaserSmartTM , gør Neato rent når og hvor du ønsker det, også når det er mørkt.
Neato D8
Neato D8 leveres med branchens første signaturkvalitet og -teknologi, som du er vant til at forvente fra Neato – som fx den største støvbeholder, ekstra bred børste og den seneste LaserSmartTM -teknologi – med en bedre brugeroplevelse, en køretid på op til 90 minutter og forbedret effektiv rengøring.
Den nye produktserie vil være tilgængelig i efteråret 2020 hos vores detailhandlere i hele Nordamerika, Europa og Japan, samt i USA på NeatoRobotics.com .
Om Neato
Neato Robotics udvikler intelligente robotter til hjemmet for at gøre livet nemmere for folk og løse reelle problemer. Neato er engageret i at skabe en ægte brugerdefineret rengøringsoplevelse, hvor vi sikrer, at robotterne udvikles og tilpasses til forbrugeren. Neato driver innovation med intelligent LaserSmartTM LIDAR-baseret navigation, kortlægning, smart hjemmeopkobling og uovertruffen rengøringsteknologi. Få mere at vide på www.neatorobotics.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200904005047/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
